Creso looks to expand product range following successful Swiss launch
Creso Pharma Limited (ASX:CPH) has today informed the market of its commitment to expand the commercialisation and distribution of anibidiol®, its CBD-based complementary animal feed product.
These plans come on the heels of the product’s successful launch in Switzerland in November 2017 — which it conducted with animal pharmaceutical giant Virbac Switzerland — resulting in early revenue for the company (already banked) and generated positive feedback from customers and veterinarians.
CPH is now in the process of planning the commercialisation of the anibidiol® range across global markets in CY2018 and beyond. This product expansion will involve tapping into the significant US$9.8 billion global companion animal market.
However, how much of the market CPH is able to corner is speculative at this stage and therefore investors shouldn’t act on this fact alone, but should take all publicly available information into account and seek professional financial advice.
Managing Director of Virbac Switzerland Rolf Heeb commented on the news: "We have been assured by the interest from vets that it was the right move and the right time to launch anibidiol®. There has been great interest from both vets and pet owners since its launch."
Swiss veterinarian Dr Fabian Huwiler provided support for this view, stating of the product: “anibidiol® is a unique natural, organic and efficient feed supplement improving the quality of life of the pet and the pet owner; we were waiting for such a product.”
According to CPH’s announcement, the global animal health market is valued at US$30 billion and is projected to continue to grow at a fast pace; with 41 percent of pet owners considering or trying out various alternative therapies for their pets.
In commenting on these developments, CPH Co-Founder and Chief Executive Officer Dr Miri Halperin Wernli said: “This promising start with anibidiol® in Switzerland sets a very sound foundation for Creso Pharma to progress into the international market arena.”
CPH is in the process of expanding the anibidiol® range through the development of additional lifecycle products for companion animals. It plans to team up again with Swiss pharmaceutical animal health company Virbac for further launches in Switzerland in 2018.
anibidiol® is a natural complementary feed for pets which contains full spectrum hemp extract with cannabidiol (CBD), the non-psychoactive substance of the hemp plant, as well as hemp seed oil. anibidiol® is a proprietary product which combines not only CBD, but fatty acids Omega 3, Omega 6 and Omega 9, as well as terpenes, flavonoids, and other active herbal ingredients.
The product’s ingredients interact in a complex way which, in the words of the company, “enhances their overall health-promoting effect”. anibidiol® is the first Swiss Agroscope conformed complementary feed for companion animals that contains natural hemp extract with CBD and is THC-free.
When the experts at Next Investors have a stock pick, it may pay to listen.
The Next Investors have been investing in ASX small cap stocks for years, with their best small cap picks yielding returns of 1,200%, 1,120%, 900% and 678%.
They have just revealed their hand-picked, FY2021 stock portfolio of high conviction long-term investments.
Click the link below to see what they are currently investing in.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.